Investment Thesis
10x Genomics maintains exceptional financial strength with $490M cash, zero debt, and positive free cash flow of $24.5M despite net losses, indicating underlying business viability. However, the company's -11.3% operating margin and unprofitability at scale, combined with modest 5.2% revenue growth, require a clear demonstration of margin expansion before an upgrade is warranted.
Strengths
- Exceptional balance sheet with $490M cash and zero long-term debt provides significant financial flexibility
- Strong gross margins of 70.4% demonstrate product quality and pricing power in laboratory analytics markets
- Positive operating cash flow of $26.1M and free cash flow of $24.5M (16.3% FCF margin) indicate sustainable business fundamentals despite net losses
- Excellent liquidity with 5.90x current ratio and minimal capex requirements of $1.6M provide runway for operations
Risks
- Operating loss of $17.0M and negative net margin of -8.9% at revenue scale of $151M suggests structural profitability challenges or inefficient cost structure
- Negative return metrics (ROE -1.7%, ROA -1.3%) indicate current value destruction despite strong balance sheet
- Modest revenue growth of 5.2% YoY insufficient to demonstrate scale potential in laboratory instruments sector
- Significant gap between positive FCF and negative net income suggests material non-cash charges or accounting items masking operational challenges
- Unprofitability trend unsustainable long-term even with $490M cash buffer without clear cost management plan
Key Metrics to Watch
- Operating margin progression and path to breakeven within 12-24 months
- Revenue growth acceleration above 5% to demonstrate market demand
- Operating cash flow sustainability and working capital efficiency
- Gross margin stability and operating expense ratio trends
Financial Metrics
Revenue
150.8M
Net Income
-13.5M
EPS (Diluted)
$-0.10
Free Cash Flow
24.5M
Total Assets
1.0B
Cash
490.3M
Profitability Ratios
Gross Margin
70.4%
Operating Margin
-11.3%
Net Margin
-8.9%
ROE
-1.7%
ROA
-1.3%
FCF Margin
16.3%
Balance Sheet & Liquidity
Current Ratio
5.90x
Quick Ratio
5.42x
Debt/Equity
0.00x
Debt/Assets
19.8%
Interest Coverage
-17,046.00x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:34:23.319776 |
Data as of: 2026-03-31 |
Powered by Claude AI